Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Viemed Healthcare (VMD) EBITDA (2018 - 2025)

Viemed Healthcare's EBITDA history spans 8 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 29.74% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $22.9 million, up 32.66%, while the annual FY2025 figure was $22.9 million, 103.72% up from the prior year.
  • EBITDA reached $8.4 million in Q4 2025 per VMD's latest filing, up from $5.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8.4 million in Q4 2025 to a low of $1.0 million in Q2 2022.
  • Average EBITDA over 5 years is $3.3 million, with a median of $2.7 million recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 91.95% in 2021, then soared 150.13% in 2023.
  • A 5-year view of EBITDA shows it stood at $4.1 million in 2021, then tumbled by 42.45% to $2.4 million in 2022, then skyrocketed by 45.97% to $3.5 million in 2023, then skyrocketed by 85.56% to $6.5 million in 2024, then increased by 29.74% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's EBITDA are $8.4 million (Q4 2025), $5.6 million (Q3 2025), and $5.1 million (Q2 2025).